2113: Improvement in Key PsA Core Domains with Guselkumab Treatment in an Enriched Population of ACR20 Non-Responders at Week 24: Post Hoc Analysis of Two Phase 3 Studies

McGonagle, D., Haaland, D., Helliwell, P. et al. (6 more authors) (2022) 2113: Improvement in Key PsA Core Domains with Guselkumab Treatment in an Enriched Population of ACR20 Non-Responders at Week 24: Post Hoc Analysis of Two Phase 3 Studies. In: Arthritis & Rheumatology. ACR Convergence 2022, 10-14 Nov 2022, Philadelphia, USA. , pp. 4182-4184.

Metadata

Authors/Creators:
  • McGonagle, D.
  • Haaland, D.
  • Helliwell, P.
  • Marrache, A.M.
  • Shawi, M.
  • Rampakakis, E.
  • Nash, P.
  • Palazuelos, F.I.
  • Kavanaugh, A.
Dates:
  • Published (online): 29 September 2022
  • Published: 29 September 2022
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Inflammatory Arthritis (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 22 Aug 2023 13:33
Last Modified: 22 Aug 2023 13:33
Status: Published
Identification Number: https://doi.org/10.1002/art.42355
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics


CORE (COnnecting REpositories)